GLP-1RAs防治糖尿病肾病的临床研究进展  

Clinical research progress of GLP-1RAs in the prevention and treatment of diabetic kidney disease

作　　者：胡晓澜 张瑜 黄莉吉[3] 谢绍锋[1] HU Xiaolan;ZHANG Yu;HUANG Liji;XIE Shaofeng(Endocrinology Department,Affiliated Hospital of Traditional Chinese and Western Medicine Nanjing University of Chinese Medicine/Nanjing University of Chinese Medicine Third Clinical Medical College,Nanjing 210028;Geriatrics Medicine Department,Huishan District People's Hospital of Wuxi City,Wuxi 214187;Endocrinology Department,Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210029,China)

机构地区：[1]南京中医药大学附属中西医结合医院内分泌科/南京中医药大学第三临床医学院,江苏南京210028 [2]无锡市惠山区人民医院老年医学科,江苏无锡214187 [3]南京中医药大学附属医院内分泌科,江苏南京210029

出　　处：《临床医学研究与实践》2023年第30期191-194,共4页Clinical Research and Practice

基　　金：2019年度江苏省中医药科技发展计划项目(No.YB201910)。

摘　　要：胰高血糖素样肽-1受体激动剂(GLP-1RAs)是一种作用于肠促胰岛素的新型降糖药物,因其降血糖效果显著,低血糖发生风险小,越来越多地应用于2型糖尿病(T2DM)的治疗。近年来的多项大型临床研究表明,GLP-1RAs还能减少T2DM患者蛋白尿排泄,降低复合肾脏结局事件的发生风险,具有肾脏保护作用。本文就近年来有关GLP-1RAs对糖尿病肾病(DKD)肾脏保护作用的大型临床研究做一综述,以期为临床实践提供思路与依据。Glucagon-like peptide-1 receptor agonists(GLP-1RAs)are a new type of hypoglycemic drugs acting on incretins.Because of their significant hypoglycemic effect and low risk of hypoglycemia,they are increasingly used in the treatment of type 2 diabetes mellitus(T2DM).In recent years,a number of large-scale clinical studies have shown that GLP-1RAs can also reduce proteinuria excretion in patients with T2DM,reduce the risk of composite renal outcome events,and have a renal protective effect.This article reviews the large-scale clinical studies on the renal protective effect of GLP-1RAs on diabetic kidney disease(DKD)in recent years,in order to provide ideas and basis for clinical practice.

关 键 词：胰高血糖素样肽-1受体激动剂 糖尿病肾病 肾脏保护作用 

分 类 号：R587.1[医药卫生—内分泌]